d liposomal doxorubicin; NR = not reported; NRe = not reachedРAvastin+CP Avastin维持一线治疗卵巢癌的 II 期临床试验–试验设计Р主要研究终点:毒性, RR 和 PFSР*Eligible patients had epithelial ovarian, primary peritoneal, fallopian tube or papillary serous müllerian carcinoma?‡Avastin was not administered with the first cycle of carboplatin/paclitaxel?Penson, et al. JCO 2010Р新诊断的?≥IC期卵巢癌* (n=62)РCarboplatin (AUC 5)/ paclitaxel 175mg/m2?q3w x6–8 + Avastin 15mg/kg q3w‡РAvastin 15mg/kg q3w?for 12 monthsРAvastin+CP Avastin维持一线治疗卵巢癌的 II 期临床试验–特性РCharacteristicР(n=62)РMedian age, years (range)Р58 (18–77)РPerformance status (%)Р1Р68Р2Р32РFIGO stage (%)РEarlyР10РIIIР69РIVР21РPrimary site (%)РOvaryР73РPrimary peritonealР16РFallopian tubeР8РUterine papillary serousР5РCytoreduction (%)РOptimalР79РSuboptimalР21РPenson, et al. JCO 2010
全文预览
